Login / Signup

Thyroid eye disease: Redefining its management-A review.

Amy Patel JainPimkwan Jaru-AmpornpanRaymond S Douglas
Published in: Clinical & experimental ophthalmology (2021)
Thyroid eye disease (TED) is a debilitating, vision threatening disease that dramatically alters patients' quality of life. Until recently, the management of TED is a long arduous course with supportive therapy, followed by an extensive surgical treatment plan to reverse the disease endpoints. Teprotumumab offers an early, safe therapeutic intervention to help reverse disease end points such as diplopia and proptosis and improve quality of life.
Keyphrases
  • randomized controlled trial
  • end stage renal disease
  • chronic kidney disease
  • newly diagnosed
  • stem cells
  • ejection fraction
  • prognostic factors
  • mesenchymal stem cells